H1 Closes $40M Funding Round From CVS Health, Betting on Clinical Research Data

Healthcare data startup H1 has raised $40 million in a funding round led by CVS Health Ventures. The investment underscores growing demand among pharmaceutical and medical device companies for better tools to find and recruit the right doctors and researchers for clinical trials and drug development work.

What H1 Does

H1 builds a searchable database of healthcare professionals — doctors, clinical trial researchers, and medical thought leaders — paired with analytics tools. Pharmaceutical companies, contract research organizations, and device makers use it to identify which doctors run clinical trials, who publishes research in specific disease areas, and where patient populations match their trial needs.

The platform combines structured data on physician specialties, past research, publications, and hospital affiliations with machine learning tools that analyze medical literature and patent filings to surface connections. Think of it as a professional networking database, but built specifically for the drug development workflow — helping companies route their investigator outreach, manage relationships with research centers, and speed up trial site selection.

Why CVS Health Is Investing

CVS Health Ventures, the investment arm of the healthcare company, led the round as part of a broader strategy to back health technology companies. CVS already operates more than 9,000 retail pharmacies, runs a pharmacy benefit manager, and insures roughly 34 million people through its Aetna subsidiary. That gives the company access to vast amounts of patient data and real-world insights — information about which patients actually take which drugs, how they respond, and what health outcomes they achieve.

By backing H1, CVS positions itself to participate in an emerging market while potentially linking H1's doctor and researcher networks with CVS's patient data. As clinical trials increasingly incorporate real-world evidence — data gathered from actual patient populations outside the laboratory setting — the line between traditional drug research and everyday healthcare delivery has begun to blur.

The Broader Market Opportunity

Pharmaceutical companies face mounting pressure to speed up drug development and cut costs. A pivotal clinical trial now costs approximately $41 million on average, according to industry surveys, making efficient site and investigator selection financially critical. At the same time, the FDA has pushed companies to include more diverse patient populations in trials, which requires better tools to map out where specific patient groups are treated and which doctors have access to them.

This market remains fragmented. Established companies like IQVIA and Veeva Systems offer competing products, as do smaller specialized vendors. But the space is still consolidating — buyers increasingly want integrated platforms that handle the entire clinical trial workflow rather than piecing together separate tools.

From a market perspective, we have seen this pattern play out before in enterprise software. When a market is young, competition tends to fracture around point solutions — tools that do one thing well. Over time, buyers realize they want these capabilities bundled together, and the market consolidates around more comprehensive platforms. The question for H1 is whether it can expand beyond its core investigator database to become a broader clinical operations platform.

Potential Integration Points With CVS

The partnership opens avenues that could strengthen H1's competitiveness. CVS operates MinuteClinic, a chain of retail health centers that could serve as a distributed network of clinical trial sites — useful for decentralized trials that don't require people to travel to major medical centers. CVS also runs specialty pharmacies that treat patients with complex conditions, many of whom are candidates for follow-on studies or long-term research registries.

More ambitiously, CVS's ability to track patient outcomes across insurance claims and pharmacy transactions could complement H1's researcher-focused data. Combined, the two could help pharmaceutical companies not only identify the right investigators but also predict which patient populations will be easiest to recruit and what outcomes they're likely to achieve.

Real Challenges Ahead

For H1 to scale, it must maintain data quality and coverage across different countries and regions — a harder problem than it might sound. Doctor licensing, credentials, and hospital affiliations vary from country to country. Adding international data means dealing with fragmented sources and different regulatory rules.

Privacy regulations pose another constraint. Laws like Europe's GDPR and emerging state-level privacy rules in the US limit how much professional data companies can collect and process without consent, especially when combining information from multiple public sources. H1 has to balance building a comprehensive, useful database with respecting those boundaries.

Technically, the company also needs to keep improving its machine learning capabilities. As medical literature, patent filings, and trial registries grow, H1's ability to automatically identify emerging research areas, predict which doctors will be interested in specific trials, and suggest novel research collaborations will likely determine how competitive it stays.

What's Next

The funding gives H1 resources to expand its data coverage, improve its analytics, and push into new geographic markets. Its position at the intersection of healthcare data and drug development puts it in a good spot to benefit as pharmaceutical companies continue digitizing and automating their research operations.

The CVS partnership also hints at possible expansion beyond the traditional pharmaceutical customer base. Medical device companies, diagnostic makers, and academic hospitals that run their own research programs might all be candidates for a platform that bridges the gap between healthcare delivery and clinical research — a capability that will likely grow more valuable as hospitals embed research operations deeper into their care delivery workflows.